During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
MedPage Today on MSN2d
Upfront TKI for Bone-Predominant RCC Tops Single-Agent ImmunotherapyMedian overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...
Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...
People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...
Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...
The U.S. FDA has granted orphan drug designation to Eisai's (OTCPK:ESALF) Lenvima (lenvatinib) for esophageal cancer. The ...
Merck is however eyeing first-line treatment as a combination with Eisai’s kinase inhibitor Lenvima (lenvatinib), with new data from the KEYNOTE-524 trial of the regimen also reported at this ...
The list including Bristol-Myers Squibb’s cancer immunotherapy Opdivo (nivolumab), Eli Lilly’s Cyramza (ramucirumab), Eisai’s Lenvima (lenvatinib), Bayer’s Stivarga (regorafenib) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback